Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Massard

Showing results (41-50 of 365) with videos related to

Pageof 37
Sort By:
Bulletin Du Cancer|February 3, 2016
[A point on a new year]Jacques-Olivier Bay, Gilles L'Allemain, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2016
Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trialAntonin Levy, Christophe Massard, Jean-Charles Soria, et al.
Cancer|April 30, 2009
Sequential therapy in renal cell carcinomaBernard Escudier, Marine Gross Goupil, Christophe Massard, et al.
Investigational New Drugs|August 4, 2009
Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimusChristophe Massard, Karim Fizazi, Marine Gross-Goupil, et al.
Bulletin Du Cancer|September 13, 2007
[Locally advanced prostate cancer: definition, prognosis and treatment]Anne Plantade, Christophe Massard, Renaud de Crevoisier, et al.
Bulletin Du Cancer|February 10, 2015
[2015, an evolution without revolution, a change within continuity]Jacques-Olivier Bay, Gilles L'Allemain, Christophe Massard, et al.
Bulletin Du Cancer|July 4, 2016
[Standard of care of carcinomas on cancer of unknown primary site in 2016]Marc-Antoine Benderra, Marius Ilié, Paul Hofman, et al.
Bulletin Du Cancer|August 9, 2011
[High dose chemotherapy and germ cell tumor]Christophe Massard, Aude Fléchon, Karim Fizazi, et al.
Bulletin Du Cancer|March 28, 2015
[Editorial]Gilles L'Allemain, Stéphane Vignot, Christophe Massard, et al.
Bulletin Du Cancer|March 31, 2015
[Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]Christophe Massard, Jean-Jacques Patard, Olivier Hermine, et al.
Pageof 37

Showing results (41-50 of 365) with videos related to

Sort By:
Pageof 37
Bulletin Du Cancer|February 3, 2016
[A point on a new year]Jacques-Olivier Bay, Gilles L'Allemain, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2016
Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trialAntonin Levy, Christophe Massard, Jean-Charles Soria, et al.
Cancer|April 30, 2009
Sequential therapy in renal cell carcinomaBernard Escudier, Marine Gross Goupil, Christophe Massard, et al.
Investigational New Drugs|August 4, 2009
Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimusChristophe Massard, Karim Fizazi, Marine Gross-Goupil, et al.
Bulletin Du Cancer|September 13, 2007
[Locally advanced prostate cancer: definition, prognosis and treatment]Anne Plantade, Christophe Massard, Renaud de Crevoisier, et al.
Bulletin Du Cancer|February 10, 2015
[2015, an evolution without revolution, a change within continuity]Jacques-Olivier Bay, Gilles L'Allemain, Christophe Massard, et al.
Bulletin Du Cancer|July 4, 2016
[Standard of care of carcinomas on cancer of unknown primary site in 2016]Marc-Antoine Benderra, Marius Ilié, Paul Hofman, et al.
Bulletin Du Cancer|August 9, 2011
[High dose chemotherapy and germ cell tumor]Christophe Massard, Aude Fléchon, Karim Fizazi, et al.
Bulletin Du Cancer|March 28, 2015
[Editorial]Gilles L'Allemain, Stéphane Vignot, Christophe Massard, et al.
Bulletin Du Cancer|March 31, 2015
[Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]Christophe Massard, Jean-Jacques Patard, Olivier Hermine, et al.
Pageof 37